Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform.
Shares in Immupharma, the London-based drug discovery and development company, jumped 20% to 2.55 pence early on Tuesday afternoon.
P140 is ImmuPharma’s technology platform for its portfolio in autoimmune diseases. This comprises the lead indication commencing a phase 3 clinical study in systemic lupus erythematosus and the second indication, in preparation for a phase 2/3 adaptive clinical study in chronic idiopathic demyelinating polyneuropathy.
ImmuPharma said the new patent initiative will strengthen the commercial value of P140 and add to the ‘positive engagement we are already experiencing in discussions with a broad range of potential commercial partners on SLE and CIDP.’
It said new patents will not only ‘significantly enhance the patent protection for P140 in SLE and CIDP but will also support patient studies in other auto-immune/inflammatory diseases and release further value from the P140 technology platform.’
Chief Executive Tim McCarthy called it an ‘important’ new initiative which will ‘greatly improve the intellectual property protection for our P140 technology platform and extend its patent life significantly.’
Copyright 2024 Alliance News Ltd. All Rights Reserved.
